New inhaled therapy tested to slow scarring of the lungs
NCT ID NCT07194382
Summary
This study is testing whether inhaling a drug called nintedanib (AP02) can help slow down lung scarring in people with Idiopathic Pulmonary Fibrosis (IPF). About 160 adults with IPF will be randomly assigned to receive one of two doses of the inhaled drug or a placebo (an inactive substance) for 12 weeks. Researchers will measure changes in lung function and scarring to see if the treatment is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.